Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a traditional chinese granule ease a common cancer treatment side effect?

NCT ID NCT07355361

First seen Jan 24, 2026 · Last updated Jun 23, 2026 · Updated 18 times

Summary

This study tests whether adding Huaier Granule to standard care can reduce proteinuria (excess protein in urine) in breast cancer patients who developed it as a side effect of immunotherapy or anti-angiogenic therapy. About 120 women will be randomly assigned to receive either standard care alone or standard care plus Huaier Granule for up to 24 weeks. The main goal is to see if the combination improves proteinuria treatment response after 8 weeks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROTEINURIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, 200032, China

    Contact Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Huaier Granule

What this could lead to

If it works, this could offer a new way to manage proteinuria as a side effect of cancer treatment, potentially improving quality of life for breast cancer patients.

What could go wrong

This is a small Phase 2 trial, so results are preliminary. The granule may not reduce proteinuria better than standard care, and its long-term safety is not yet established.

Conditions

The condition(s) this trial relates to.

proteinuria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.